The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 24, 2023
Filed:
Mar. 05, 2021
Substituted 6-membered aryl or heteroaryl allosteric modulators of nicotinic acetylcholine receptors
Applicant:
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Inventors:
Brendan M. Crowley, Collegeville, PA (US);
Ian M. Bell, Harleysville, PA (US);
Andrew John Harvey, Paddington, AU;
Assignee:
Merck Sharp & Dohme LLC, Rahway, NJ (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/695 (2006.01); A61K 31/198 (2006.01); A61K 31/4164 (2006.01); A61K 31/4196 (2006.01); A61K 31/4245 (2006.01); A61K 31/4418 (2006.01); A61K 31/4439 (2006.01); A61K 31/4965 (2006.01); A61K 31/50 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 213/34 (2006.01); C07D 233/64 (2006.01); C07D 237/08 (2006.01); C07D 239/26 (2006.01); C07D 241/12 (2006.01); C07D 249/08 (2006.01); C07D 271/06 (2006.01); C07D 401/04 (2006.01); C07D 413/04 (2006.01); C07F 7/08 (2006.01);
U.S. Cl.
CPC ...
A61K 31/695 (2013.01); A61K 31/198 (2013.01); A61K 31/4164 (2013.01); A61K 31/4196 (2013.01); A61K 31/4245 (2013.01); A61K 31/4418 (2013.01); A61K 31/4439 (2013.01); A61K 31/4965 (2013.01); A61K 31/50 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 213/34 (2013.01); C07D 233/64 (2013.01); C07D 237/08 (2013.01); C07D 239/26 (2013.01); C07D 241/12 (2013.01); C07D 249/08 (2013.01); C07D 271/06 (2013.01); C07D 401/04 (2013.01); C07D 413/04 (2013.01); C07F 7/0812 (2013.01);
Abstract
The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation